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CASE STUDIES
Three Endocrine Neoplasms:
An Unusual Combination of Pheochromocytoma,
Pituitary Adenoma, and Papillary Thyroid Carcinoma
James C. Sisson,1 Thomas J. Giordano,2,3 and Anca M. Avram1
Background: Three endocrine neoplasms—bilateral pheochromocytomas, somatotrophic pituitary adenoma
inducing acromegaly, and papillary carcinoma of the thyroid—occurred concurrently in a patient. A genetic
mutation was hypothesized. Possible previously described genetic mutations were explored.
Methods: Clinical assessments, laboratory data, images of tumors, histopathology, and immunohistochemistry
of excised tissues documented the three neoplasms. Clinical assessment of the patient, family history, and a
review of the literature sought a familial basis for the disorders.
Results: The methods confirmed the presence of three endocrine neoplasms. Each neoplasm was surgically
excised and histologically verified. Surgical and 131I treatments reduced the papillary carcinoma, but eventually
this tumor progressed to a lethal degree. History, including that of nine siblings, uncovered no familial neo-
plasms. No similar case was found in the literature, but possible associations with germline mutations were
considered.
Conclusions: The concurrent development of pheochromocytomas, pituitary somatotrophic adenoma, and
papillary thyroid carcinoma appears to be unique. Nevertheless, such tumors, particularly bilateral pheochro-
mocytomas, strongly suggest a de novo germline mutation in a gene not previously associated with multiple
endocrine neoplasia syndromes.
Introduction
Certain combinations of endocrine neoplasms, tumorsthat are generally functioning, have been shown to be
familial. Multiple endocrine neoplasia type 1 (MEN-1), first
described in 1954 (1), included hyperparathyroidism arising
from multiple parathyroid adenomas, pituitary tumors
of various types including prolactinomas and somatrophic
adenomas, and neuroendocrine tumors arising in the pan-
creas including gastrinomas and insulinomas. Mutations of
the MENIN gene were determined to be the source of the
clinical manifestations of MEN-1 (2).
The features of MEN-2, medullary carcinoma of the thyroid
(MTC), pheochromocytomas, and hyperparathyroidism
derived from parathyroid gland hyperplasia, were first
described in 1961 (3), but it soon became clear that a subset
of patients exhibited MTC, pheochromoctyomas, and pro-
nounced facial features from ganglioneuromas, but not hy-
perparathyroidism (4). The former combination of familial
tumors was designated MEN-2A and the latter, MEN-2B.
Germline mutations of the RET protooncogene underlie these
multiple endocrine disorders (5).
Variations in the specific mutations of oncogenes have
generated diverse phenotypic appearances in affected indi-
viduals. However, none have exhibited the combination of the
three endocrine neoplasias—bilateral pheochromocytomas,
somatotrophic pituitary adenoma, and papillary carcinoma of
the thyroid—manifested in our patient.
Case Presentation
When initially evaluated at the University of Michigan
Health System in December 1996, the patient was a 29-year-
old male carpenter. For about 2 years, he was afflicted by
headaches and diaphoresis, both day and night. His elevated
blood pressure was unmitigated by medications, including
atenolol 25 mg/day. Yet, he continued to work regularly. In
November 1996, a search for a cause of secondary hyperten-
sion included a CT that portrayed bilateral adrenal enlarge-
ments attributable to pheochromocytomas (Fig. 1A, B). He
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had no visual symptoms. Libido and erectile function were
reported to be normal.
He weighed 118 kg and stood 188 cm. Blood pressure was
170/116 and heart rate was 72 beats/min. Soft tissue swelling
was prominent in his large hands and feet. His shoe size was
13 but was recently unchanged. Thickened skin was damp
from perspiration. A number of small skin lesions were ob-
served; one appeared to be a lipoma, but none were charac-
teristic of a myxoma or a neurofibroma. Readily apparent
were a large brow and an overbite in a prominent jaw. No
abnormality was detected in either his visual fields or extra-
ocular muscle movements. His tongue was expansive. Palp-
able enlargement of his left thyroid lobe was accompanied by
two easily discerned lymph nodes in his left neck.
He was never married and had no children. Nine siblings
were described: six sisters were 2–19 years older, and three
brothers were 4–18 years older. None had developed the
stigmata observed in the patient. Although one brother was
said to be large, a family picture showed none of the siblings
to be as tall as the patient. A sister died at age 45 years of a
‘‘heart problem.’’ The eldest sister had been diagnosed with
heart disease. His father developed Hodgkin’s disease and
prostate cancer; he died at age 72. His mother died of meta-
static uterine cancer at age 69. Maternal and paternal grand-
parents, and uncles and aunts lived to old ages. Nieces and
nephews were reported to be in good health. The family
heritage was Polish, German, and Bahamian.
Analysis of urine showed elevated excretion rates of epi-
nephrine (87 lg/24 hours; normal £ 20), norepinephrine
(1090 lg/24 hours; normal £ 100), and vanillylmandelic acid
(26 mg/24 hours; normal £ 10). The serum level of insulin-like
growth factor (IGF-1) was elevated at 1048 ng/mL (normal
£ 380), but the growth hormone (GH) concentration was
normal. Concentrations of serum calcium, phosphorus, and
parathormone were normal. Serum prolactin (PRL) was
subnormal (2.0 ng/mL; normal 3.0–23.0), as was serum tes-
tosterone (2.0 ng/mL; normal 2.5–9.5).
MRI images of the sella turcica depicted a pituitary ade-
noma without extension into the suprasellar space or the
cavernous sinus (Fig. 2); the floor of the sella was not opti-
mally visualized.
During phenoxybenzamine therapy on January 22, 1997,
the pheochromocytomas were excised by bilateral total
adrenalectomies. The surgeon reported that ‘‘there did not
appear to be any normal adrenal gland remaining’’ on the
right side. The pathologist recorded complete adrenalec-
tomies; the right adrenal gland was the larger and contained
two pheochromocytomas, while the left gland contained a
pheochromocytoma as well as nodular medullary hyperpla-
sia (Fig. 3A, B). Bilateral pheochromocytomas with medullary
hyperplasia are typical of those observed in familial cases.
FIG. 1. CT images of abdomen at adrenal gland levels, November 1996. Arrows point to the depicted abnormalities: (A) a
4 cm · 5 cm soft mass in the right adrenal gland, and (B) a 3 cm · 2.5 cm mass in the left adrenal gland. In the context of
elevated urinary catecholamine and catecholamine metabolite excretion, the images are attributable to bilateral adrenal
pheochromocytomas.
FIG. 2. Gadolinium-enhanced MRI image of sella turcica in
December 1996 demonstrates a central region of diminished
enhancement within the gland attributable to a pituitary
adenoma (thick arrow); immediately inferior to the region is
a large mucosal retention cyst within the sphenoid sinus
(thin arrow).
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A prior ultrasound-guided fine needle biopsy enabled as-
piration of papillary carcinoma cells from the left thyroid
nodule, and, thus, under the same anesthesia, a total thyroid-
ectomy removed a nodular left lobe and normal-appearing
right lobe, isthmus, and pyramidal lobe. Multiple enlarged
nodes were dissected free from the left neck. Histologic ex-
aminations displayed extensive primary papillary carcinoma
that replaced most of the left lobe and also involved the right
lobe. The majority of the tumor displayed a follicular growth
pattern, but areas of papillary architecture were present
(Fig. 4A, B). The tumor was invasive and extended into ex-
trathyroidal tissues. Numerous cervical lymph nodes con-
tained metastatic papillary carcinoma. Postoperative daily
maintenance therapy consisted of hydrocortisone in divided
doses, 15, 10, and 5 mg; fludrocortisone 0.1 mg; and thyrox-
ine 0.2 mg.
In March 1997, thyroxine therapy was temporarily with-
held, and serum thyrotropin (TSH) rose to 51 mU/mL (nor-
mal 0.3–5.0), and thyroglobulin was 74 ng/mL. He was
treated with 7.4 GBq (200 mCi) of 131I, and 2 days later whole
body scintiscans revealed 3 foci of radioactivity in his left
neck, and smaller foci in his right neck (Fig. 5A). Over the
subsequent years his thyroxine dose was changed in efforts,
not always successful, to suppress his TSH below 0.1 mU/L.
On March 21, 1997, a transphenoidal resection appeared to
have completely removed his pituitary adenoma. The tumor
was strongly positive for chromogranin A and focally positive
for growth hormone (Fig. 6). The postoperative value for IGF-
1 was lower but still elevated at 506 ng/mL. Medications were
unchanged at this discharge from the hospital. Re-evaluation
on April 30, 1997, recorded his blood pressure as 150/80 sit-
ting and standing, and he weighed 120 kg.
On April 1, 1998, a scintiscan displayed foci of radioactive
iodine in his neck that were less intense than in 1997, but his
hypothyroid-stimulated thyroglobulin concentration was
higher (191 ng/mL). A second treatment with 131I, 7.4 GBq,
was administered. Subsequent care was complicated by
miscommunications between patient and physicians.
FIG. 3. Histopathology of bilateral and multifocal pheochromocytomas. (A) The right adrenal gland weighed 52 g and
contained two distinct brown masses, 4.5 and 1.7 cm in greatest dimension. Both masses displayed typical features of
pheochromocytomas with a nested growth patterns and large cells with abundant granular cytoplasm. (B) The left adrenal
gland weighed 21 g and contained a brown mass 2 cm in greatest dimension. This mass also displayed typical features of
pheochromocytoma. In addition, there was evidence of nodular medullary hyperplasia (not shown). Features associated with
malignant behavior were not observed in any of the tumors. Original magnification, 200 · .
FIG. 4. Primary and metastatic papillary thyroid carcinoma. (A) Primary tumor replaced the left lobe with multiple nodules
of well-differentiated papillary carcinoma, most displaying the features of the follicular variant. Neoplastic follicular cells and
papillae show the classical nuclear features of this carcinoma. (B) Follicular variant of papillary carcinoma involving one of
the cervical lymph nodes. Original magnification, 200 · .
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While hypothyroid in June 2005, imaging with single-
photon tomography of diagnostic 131I combined with CT
showed lung nodules and hilar nodes containing radioactiv-
ity. He received his third treatment, another 7.4 GBq of 131I;
images of this radioactivity prominently displayed the me-
tastases (Fig. 5B).
In September and December of 2005, he felt well and was
working regularly. Under thyroxine suppression, his thyro-
globulin had declined to 22 ng/mL. During the latter evalu-
ation, a CT with contrast medium demonstrated a large hilar
node, but no change in small lung metastases; also portrayed
was adrenal gland tissue not dissimilar from the original
normal gland (Fig. 7).
He returned on July 5, 2007, feeling well and working
regularly. However, his prescriptions for hydrocortisone and
fludrocortisone had expired 2 months previously, and he was
without these medications thereafter. Thyroxine was contin-
ued at 0.2 mg/day. His weight was unchanged from the
previous visit; his blood pressure was 137/85 and his heart
rate, in beats/min, was 40 while sitting and 54 standing. There
was no increased pigmentation of his skin or oral mucus
membranes. Assessments of adrenal cortex function gave
plasma levels of adrenocorticotrophic hormone (ACTH),
36 pg/mL (normal 9–52), and cortisol 0.15 mg/L (normal
0.07–0.32). It was apparent that he harbored accessory adrenal
cortical tissue, and hydrocortisone and fludrocortisone were
not re-prescribed. While his TSH remained suppressed, his
serum thyrogobulin had risen to 112 ng/mL. His IGF-1 level
was then normal.
The patient was last seen on December 9, 2008. His weight
was unchanged; his blood pressure was 127/67 and heart rate
FIG. 5. Scintigraphic images displaying 131I concentrations.
(A) In March 1997 and 2 days following treatment with
7.4 GBq (200 mCi) of 131I, bilateral regional lymph node me-
tastases are indicated by arrows; there is physiologic radio-
activity in the stomach ({) and bladder (*). (B) In June 2005
and 2 days after the third 7.4 GBq treatment, image portrays
bilateral pulmonary metastases (arrowheads) along with hi-
lar and mediastinal nodal metastases; the cervical lymph
nodal activities seen in (A) have disappeared.
FIG. 6. Pituitary adenoma. The tumor displayed a typical
growth pattern of a well-differentiated neuroendocrine neo-
plasm with small round nuclei and abundant eosinophilic
cytoplasm. Focally, the tumor contained numerous psammo-
matous calcifications. By immunohistochemistry, the tumor
cells were strongly immunoreactive to chromogranin A, fo-
cally positive for growth hormone, and negative for follicular
stimulating hormone, luteinizing hormone, thyrotropin,
adrenocorticotrophic hormone, and PRL.
FIG. 7. In December 2005, surveillance abdominal CT
demonstrates a normal-appearing right adrenal gland (ar-
row); surgical clips in the right and left adrenal beds are
residua of bilateral adrenalectomies.
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49 beats/min. Again no lymph nodes were palpable in his
neck, and the physical examination was normal. Plasma
concentrations of ACTH and cortisol remained normal. Yet,
during thyroxine therapy, his serum thyroglobulin concen-
tration had increased further (263 ng/mL). Still, he was feel-
ing well and working regularly.
The patient developed lower right back pain in mid-2009.
In another medical center, MRI uncovered tumor in his right
pelvis; biopsy demonstrated thyroid carcinoma. Despite
treatment with external beam radiation and chemotherapy,
the neoplasm progressed to his left pelvis, vertebrae, and ul-
timately to his brain. Experimental therapy was unhelpful,
and he died on October 1, 2010.
Discussion
Our patient manifested a unique combination of endocrine
tumors: bilateral pheochromocytomas within a background
of medullary hyperplasia, pituitary adenoma secreting
growth hormone and associated with acromegaly and possi-
bly gigantism, and papillary carcinoma of the thyroid. No
known syndrome or conceivable interrelationships among
the tumors explained the combination. The family history was
unrevealing. Nevertheless, a de novo germline mutation
seemed likely.
Patients with bilateral pheochromocytomas have familial
and/or germline mutations in 59 (6) and 76 (7) percent of
cases, respectively. The bilateral tumors are most frequently
observed in Von Hippel-Lindau (VHL) disease, MEN types
2A and 2B, and neurofibromatosis type 1 (NF1) (6,7). Bi-
lateral pheochromocytomas are occasionally seen in patients
with a succinate dehydrogenase D (SDHD) mutation (7), but
have not been described in those carrying the SDHB gene.
Although mutations of SDHB and SDHD are frequently as-
sociated with pheochromocytomas, paragangliomas are also
common; the latter manifestation was not present in our
patient.
The literature offers little evidence from which to construct
further associations. Major components of VHL disease—
hemangioblastoma of the central nervous system, renal cell
carcinoma, pancreatic cysts, retinal angioma, and epididymal
cysts (8)—were absent in our patient, but possibly the latter
two features could have been overlooked. In contrast to
pheochromocytomas developing in the MEN-2 syndromes,
the tumors arising as part of VHL disease usually do not se-
crete epinephrine (9), a product which was excreted at an
elevated rate in our patient.
In addition, the almost invariable component of MEN-2,
MTC, was absent in our patient although a very small focus
could have been overlooked. A careful examination had
revealed none of the common lesions of NF1: neurofibro-
mas, café-au-lait spots, axillary freckling, and abnormality
of the iris (10).
Growth hormone–secreting pituitary adenomas have been
associated with MEN type 1 (11) and the mutation of aryl
hydrocarbon receptor–interacting protein gene (11–13).
A possible association within our patient appears in the report
demonstrating that the frequency of papillary carcinoma of
the thyroid was increased in patients with acromegaly. In 125
patients with acromegaly, 7 developed papillary carcinoma of
the thyroid, 2 of which were the follicular variant; a carcino-
genic role for IGF-1 was proposed (14).
Papillary carcinomas of the thyroid are components of the
syndrome of phosphatase and tensin PTEN homolog muta-
tion (15,16), Cowden syndrome, and familial adenomatous
polyposis (17). However, neither pheochromocytomas nor
pituitary adenomas were included in these familial associa-
tions. Nevertheless, familial non-MTCs of the papillary type
were found relatively frequently to metastasize to bilateral
cervical nodes and lead to a dire prognosis (18), as in our
patient.
Another combination has been reported; papillary carci-
noma of the thyroid was developed in a patient with bilateral
pheochromocytomas associated with a paraganglioma but
no mutation was found to indict VHL, MEN, SDHB, or
SDHD (19).
Accessory adrenal cortical tissue has been reported fol-
lowing adrenalectomies (20) and has sustained Cushing’s
syndrome in other patients (21,22). The frequency of this
anomaly is unknown, and, being nonneoplastic, the accessory
adrenal cortex maybe unrelated to the three endocrine neo-
plasms in our patient.
We could not find a link that would associate the three
endocrine tumors in our patient. Nonetheless, novel muta-
tions are frequently reported, for example, in the MEN-1 (23)
and MEN-2 (24) syndromes. It is reasonable to consider that
one or more of the germline mutations discussed previously
were at the base of our patient’s three endocrine disorders.
Unfortunately, blood was not obtained for genetic analyses
before his demise.
Addendum
Since acceptance of this manuscript by the editors of
Thyroid, the authors were made aware of a publication (25)
describing a 37-year-old man who exhibited multiple para-
gangliomas, bilateral pheochromocytomas and a growth
hormone–secreting pituitary adenoma associated with a novel
SDHD mutation; family members displayed paragangliomas.
Referenced was an article we had overlooked (26). This
study cited a previously described (27) 52-year-old woman
who manifested: a right adrenal pheochromocytoma that was
invasive, a chromophobe pituitary adenoma, and papillary
carcinoma of the thyroid.
Conclusion
We present a patient with three concurrent endocrine
neoplasms: bilateral pheochromocytomas, somatotrophic
adenoma inducing acromegaly, and metastatic papillary
carcinoma of the thyroid. Accessory adrenal cortical tissue
was also found but maybe unrelated. Family history uncov-
ered no relative with a comparable phenotype. Any one of a
number of mutations is possible, but unfortunately blood for
genetic analysis was not obtained before the patient died of
progressive thyroid carcinoma. As technology to perform
whole genome sequencing using paraffin-embedded tissue
advances, this case will be revisited in an attempt to identify a
novel gene mutation.
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